Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 65

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Granulomatosis with polyangiitis

Not yet recruiting

Study on Rituximab, Tocilizumab, and Tofacitinib for Patients with Granulomatosis with Polyangiitis Not Responding to Standard Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Cytokine release syndrome

Not yet recruiting

Study on Dasatinib for Preventing Side Effects in Patients with Relapsed or Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Universitaetsklinikum Wuerzburg AöR

Dermatitis atopic

Not yet recruiting

Study on Eblasakimab for Adults with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Aslan Pharmaceuticals Pte Ltd

Idiopathic pulmonary fibrosis

Not yet recruiting

Study on Inhaled Phospholipid Fraction from Bovine Lung for Patients with Idiopathic Pulmonary Fibrosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Phospholipid Fraction, Bovine Lung
  • Sponsor:Philipps-Universitaet Marburg

Acute graft versus host disease

Not yet recruiting

Study of RLS-0071 in Hospitalized Patients with Steroid-Resistant Acute Graft-versus-Host Disease (aGvHD)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(Discrete-Polyethylene Glycol)24
  • Sponsor:Realta Life Sciences Inc.

Asthma

Not yet recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Milk allergy+1

Not yet recruiting

Study on the Safety and Effectiveness of Low-Dose Oral Immunotherapy with Omalizumab for Children with Severe Cow's Milk Allergy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Omalizumab
  • Sponsor:Hospital Infantil Universitario Nino Jesus

Ulcerative keratitis

Not yet recruiting

Study on the Effectiveness of NANOULCOR for Patients with Severe Corneal Ulcers Using Allogenic Limbal Cells and Keratocytes

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogenic Corneal-Derived Adult Keratocytes, Ex-Vivo Expanded
  • Sponsor:Fundacion Publica Para La Investigacion Biosanitaria De Andalucia Oriental Alejandro Otero

Pulmonary sarcoidosis

Not yet recruiting

Study on the Effects of OATD-01 for Patients with Active Pulmonary Sarcoidosis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methylmorpholino)Piperidin-1-Yl)-1H- 1,2,4-Triazol-3-Amine
  • Sponsor:Molecure S.A.

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.